Consequently, we found a clear improvement in PSD95 and NeuN protein levels in 5XFAD treated with UB‐SCG‐51 compared to the 5XFAD Ct group but did not reach statistical significance (Figure 8G,I,J ).
← all excerpts
Novel molecular mechanism driving neuroprotection after soluble epoxide hydrolase inhibition: Insights for Alzheimer's disease therapeutics.
1
—
—